Media stories about CareDx (NASDAQ:CDNA) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CareDx earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.7257357624244 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- ETFs with exposure to CareDx, Inc. : November 17, 2017 (finance.yahoo.com)
- CareDx Further Simplifies its Balance Sheet (finance.yahoo.com)
- CareDx, Inc. :CDNA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 (finance.yahoo.com)
- CareDx, Inc. (CDNA) Expected to Announce Quarterly Sales of $12.01 Million (americanbankingnews.com)
A number of analysts have issued reports on the company. Zacks Investment Research downgraded CareDx from a “buy” rating to a “hold” rating in a report on Monday, September 11th. ValuEngine raised CareDx from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 26th. Raymond James Financial, Inc. raised CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price target for the company in a report on Wednesday, September 27th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $7.00 price target (up from $3.00) on shares of CareDx in a report on Tuesday, September 26th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $10.00 price target (up from $4.00) on shares of CareDx in a report on Monday, October 9th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $6.69.
CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.02. The company had revenue of $12.19 million during the quarter, compared to the consensus estimate of $12.05 million. CareDx had a negative return on equity of 993.56% and a negative net margin of 117.19%. The firm’s revenue for the quarter was down 2.3% compared to the same quarter last year. equities research analysts expect that CareDx will post -0.81 EPS for the current fiscal year.
In other news, major shareholder Neil Gagnon bought 10,642 shares of the business’s stock in a transaction dated Thursday, October 5th. The shares were acquired at an average price of $4.00 per share, for a total transaction of $42,568.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have bought 73,705 shares of company stock worth $224,339 in the last quarter. Insiders own 5.40% of the company’s stock.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
What are top analysts saying about CareDx Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CareDx Inc and related companies.